Partnership with IBM to accelerate new antibody therapies.
Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. “We are very excited to collaborate with the research team at IBM,…